Major Depressive Disorder (MDD) Treatment

Learn more about BrainsWay’s Deep TMS treatment for MDD

BrainsWay’s patented Deep TMS treatment is an innovative and effective treatment option for depression. BrainsWay D is leading a new era in the treatment and research of brain disorders. It offers relief for many patients suffering from this life-altering condition.

Introducing BrainsWay D, a non-invasive and innovative treatment that is successfully transforming the lives of patients who are suffering from Major Depressive Disorder (MDD). 33% of MDD patients are resistant to any medication and 52% fail to respond to first-line therapy. The U.S. Food and Drug Administration (FDA) cleared BrainsWay’s Deep TMS device for the treatment of depression in patients who failed to respond to antidepressant medications. The treatment is well-tolerated and has been demonstrated to be effective in several clinical trials.*

BrainsWay D‘s unique, patented treatment method stimulates deep and broad neuronal targets. The treatment involves deep magnetic stimulation of the bilateral prefrontal cortex, which has been shown to be responsible for depression, and has been shown to significantly improve depression symptoms in many patients, leading to remission in about one third of patients.

Patients who have not seen improvement in their MDD symptoms using other forms of treatment may finally find relief with BrainsWay D. Deep TMS is a comfortable, non-invasive treatment option that does not require anesthesia or hospitalization. It carries no systemic side effects.

BrainsWay Clinical Trials

BrainsWay’s added value lies in its research and clinical trials. The results from a major clinical trial[1], led to the Company’s broad FDA clearance for BrainsWay D. The 16-week double-blind, placebo-controlled clinical trial (Levkovitz et al., 2015) clearly demonstrated a statistically significant benefit with Deep TMS versus sham in all efficacy measures [(i.e., a ‑6.39 adjusted change in HDRS score with active versus -3.28 with sham (p=0.008); 32.6% achieved remission rate with active versus 14.6% with sham (p=0.0051); and 38.4% achieved response rate with active versus 21.4% with sham (p=0.0138)].

BrainsWay D Goes Beyond Medication

An independent study published in the Journal of Psychiatric Research determined that Deep Transcranial Magnetic Stimulation (dTMS) plus standard medication was significantly more effective at reducing depression levels among Major Depressive Disorder (MDD) patients compared with standard medication alone.

  • The remission rate for both the dTMS (H1-coil) group (59.7%) and the standard rTMS (figure 8-coil) group (42.7%) was significantly higher than with the control group (11.1%) in the ITT population (p < .001 and p = .001, respectively).
  • The response rate (defined as ≥50% decrease in HAM-D17) was significantly greater with dTMS plus pharmacotherapy (66.7%) than with standard rTMS plus pharmacotherapy (44.0%) (p = .04).
  • The HAM-D17 was lowered by 59% in the dTMS group, 41% in the standard rTMS group (P = 0.048), and 17% in the control group (P < 0.001 vs dTMS; P = 0.003 vs standard rTMS).

Click here for more information about this and other clinical trials conducted by BrainsWay. Currently, there are a number of ongoing clinical trials in progress in several locations. Click here for more information about trial recruitment.

Existing Treatment Options

Today there are numerous pharmacological treatment options for depression. Some patients respond well to SSRI or SNRI medications, experiencing symptom relief with minimal side effects – while others find little relief or find the side effects intolerable. This is where BrainsWay can possibly offer a viable solution. Watch this video to discover how patients overcame their battle with depression – when other treatments failed to provide relief.

To download the BrainsWay D Professional Brochure, click here.

BrainsWay D in Real Life

In real-life clinical practice settings, 20 sessions of BrainsWay’s Deep TMS resulted in remission rates that were even higher than those observed in randomized controlled clinical trials. Among patients who completed a treatment course of 30 sessions, 1 in 2 achieved full remission, suggesting a definite benefit for patients completing the full 30-session treatment regimen.

*Data on file

In a randomized controlled multi-center trial of BrainsWay D for MDD

1 in 3 patients achieved remission following 20 treatment sessions

In real clinical settings, 75% of patients showed significant response following

30 treatment sessions, and 50% achieved remission

[1] Levkovitz et al.,World Psychiatry 2015;14:64–73/2 George et al.Arch Gen Psychiatry,2010;67:507-516/3Typical treatment protocol

download brochure april.

download brochures

Find a provider
near you

Lorem ipsum dolor sit amet consectetur adipiscing elit